News Breaks |
|
|
| March 22, 2013 |
| 08:32 EDT |  | SNY | Genzyme receives positive CHMP opinion for once-daily, oral AUBAGIO
Genzyme, a Sanofi Company, announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion regarding the approval of once-daily, oral AUBAGIO for the treatment of adult patients with relapsing-remitting multiple sclerosis. The CHMP did not recommend that AUBAGIO receive a new active substance designation. Additional marketing applications for AUBAGIO are under review by regulatory authorities around the world. |
|
|
News For SNY From The Last 14 Days Check below for free stories on SNY the last two weeks. |
|
|
| May 21, 2013 |
| 07:44 EDT |  | SNY | Sachs Associates to host a forum
 Subscribe for More Information |
|
| May 20, 2013 |
| 17:26 EDT | | SNY | Regeneron, Genentech, Sanofi enter into 'Zaltrap agreement'
Subscribe for More Information |
|
| 11:27 EDT | | SNY | Appeals court reverses, remands patent ruling in Sanofi suit against Mylan, Teva
Subscribe for More Information |
|
| May 17, 2013 |
| 08:03 EDT | | SNY | Sanofi reports positive topline results from pivotal Phase III Jakarta study
Subscribe for More Information |
|
| 05:18 EDT | | SNY | Sanofi says JAK2 inhibitor for myelofibrosis met primary endpoint
Subscribe for More Information |
|
| May 15, 2013 |
| 15:16 EDT | | SNY | Sanofi systemic sclerosis treatment designated for orphan drug status
Subscribe for More Information |
|
| 05:39 EDT | | SNY | Sanofi, Regeneron announce patient enrollment in two Phase 3 trials
Subscribe for More Information |
|
| May 13, 2013 |
| 09:44 EDT |  | SNY | Several companies reportedly interested in buying Adcock Ingram, Globes says
Subscribe for More Information |
|
| 07:30 EDT | | SNY | TechConnect to host a summit
2013 National Innovation Summit is being held in Washington, D.C. on May 12-16. |
|
| May 10, 2013 |
| 11:48 EDT | | SNY | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information |
| |
|
|
|
|
